https://wsw.com/webcast/cantor20/per.xa/2339486?mobile=True
- Forums
- ASX - By Stock
- PER
- Ann: Phase IIb study of ATL1102 in DMD completes recruitment
PER
percheron therapeutics limited
Add to My Watchlist
10.0%
!
1.1¢

Ann: Phase IIb study of ATL1102 in DMD completes recruitment, page-43
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.1¢ |
Change
0.001(10.0%) |
Mkt cap ! $11.96M |
Open | High | Low | Value | Volume |
1.2¢ | 1.3¢ | 1.1¢ | $222.6K | 18.87M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
11 | 7541394 | 1.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.1¢ | 462241 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 7541394 | 0.010 |
8 | 6438144 | 0.009 |
4 | 1175000 | 0.008 |
3 | 1585000 | 0.007 |
1 | 1000000 | 0.006 |
Price($) | Vol. | No. |
---|---|---|
0.011 | 462241 | 2 |
0.012 | 2680824 | 6 |
0.013 | 1324761 | 3 |
0.014 | 2019500 | 4 |
0.015 | 1500000 | 1 |
Last trade - 13.08pm 26/06/2025 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online